54 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 54 of 54 clinical reviews.
Flibanserin (Addyi) has no FDA-approved adolescent dosing. Learn why no pediatric indication exists, what the adult approval covers, and how HSDD is managed in teens.
A comprehensive clinical review of flibanserin (Addyi) use in women with autoimmune conditions, covering pharmacology, drug interactions, trial data, and prescribing guidance for HSDD in this population.
Evidence-based guide to flibanserin (Addyi) dosing in patients with renal impairment, including pharmacokinetic data, FDA labeling, clinical trial evidence, and practical prescribing considerations.
Is flibanserin (Addyi) safe during pregnancy or breastfeeding? A clinician-grade review of FDA labeling, animal reproductive data, lactation pharmacokinetics, and practical guidance for HSDD management in the peripartum period.
A guide to flibanserin (Addyi) food and supplement interactions, including alcohol, grapefruit, CYP3A4 inhibitors, and herbal products that alter drug levels.
Evidence-based guide to flibanserin use in special populations including organ transplant recipients, women living with HIV, those with hepatic impairment, and other complex clinical scenarios.
Evidence-based guidance on what to do if you miss a dose of flibanserin (Addyi), including timing rules, safety precautions, and how skipping doses affects efficacy.
A clinical guide to monitoring flibanserin (Addyi) in premenopausal adults aged 30 to 49, covering liver function, blood pressure, alcohol screening, CNS depression risk, and CYP3A4 drug interactions.
Clinical guide to flibanserin (Addyi) overdose management, including symptoms of excess dosing, pharmacologic mechanisms, emergency treatment protocols, and prevention strategies backed by FDA labeling and trial data.
A clinician-level review of flibanserin (Addyi) regulatory approvals and rejections across the US, EU, Canada, and UK, including trial data, REMS requirements, and prescribing restrictions.
Flibanserin (Addyi) has no FDA approval, clinical trial data, or guideline support for adolescent use. This article explains the safety concerns, regulatory status, and evidence gaps for ages 12 to 17.
A clinical review of flibanserin (Addyi) safety data for premenopausal women aged 30 to 49, covering side effects, drug interactions, alcohol warnings, and monitoring recommendations.
A guide to flibanserin (Addyi) safety for women ages 18 to 29, covering the alcohol interaction, CNS effects, fertility considerations, and the BEGONIA trial data.
A detailed review of flibanserin (Addyi) safety signals, FDA rejections, REMS requirements, alcohol interaction warnings, and post-marketing surveillance data for HSDD treatment.
A clinical history of flibanserin (Addyi), from its origins as a failed antidepressant to its FDA approval for hypoactive sexual desire disorder in premenopausal women, including mechanism of action, key trials, and regulatory timeline.
Complete clinical guide to flibanserin (Addyi) dosing for adult women aged 30-49, including the standard 100 mg bedtime dose, alcohol restrictions, drug interactions, and what to expect from treatment.
Does flibanserin (Addyi) affect appetite or food cravings? A deep dive into the clinical trial data, proposed mechanisms, and what patients and prescribers need to know.
A clinician-level review of flibanserin (Addyi) and cancer risk signals: preclinical data, postmarketing surveillance, pharmacology, and what prescribers and patients need to know.
A deep dive into flibanserin (Addyi) cardiovascular safety data, including hypotension, syncope, drug interactions, and long-term heart risk. Includes BEGONIA trial data, FDA REMS requirements, and clinical management guidance.
A deep dive into how flibanserin (Addyi) affects cognitive function, CNS processing, and daily performance, with primary-literature citations, real trial data, and clinical guidance for prescribers and patients.
A comparison of compounded flibanserin vs brand-name Addyi for HSDD, covering pharmacology, clinical trial data, safety, cost, and how to choose.
A clinical breakdown of flibanserin (Addyi) pricing, generic availability, and how it compares in cost and efficacy to bremelanotide (Vyleesi) and off-label alternatives for HSDD.
A clinical review of flibanserin (Addyi) pipeline developments, new delivery systems under investigation, and the future of HSDD pharmacotherapy for premenopausal women.
A guide to flibanserin (Addyi) safety in women aged 65 and older, covering falls risk, drug interactions, renal function, and deprescribing considerations backed by clinical evidence.
Does flibanserin (Addyi) cause hair loss or skin changes? A breakdown of the clinical evidence, mechanism, trial data, and what patients should monitor.
A clinical deep-dive into how flibanserin (Addyi) affects liver function, including enzyme elevations seen in trials, the FDA hepatotoxicity warning, alcohol interaction mechanisms, and monitoring protocols for prescribers.
A clinical deep-dive into flibanserin (Addyi) manufacturing, supply chain history, shortage events, mechanism of action, and what prescribers and patients need to know in 2024.
A physician-level breakdown of how flibanserin (Addyi) works, covering its serotonin, dopamine, and norepinephrine receptor pharmacology, the BEGONIA trial data, and what the neuroscience means for clinical practice.
A deep dive into how flibanserin (Addyi) affects mood, anxiety, depression risk, and CNS function in premenopausal women with HSDD, with primary-literature citations throughout.
A clinician-level review of flibanserin (Addyi) dosing, the evidence base for microdosing approaches, REMS requirements, alcohol interaction pharmacology, and what off-label dose adjustments are supported by current literature.
Evidence-based monitoring schedule for flibanserin (Addyi), including baseline labs, liver function testing, blood pressure checks, and follow-up exam intervals.
A comprehensive clinical guide to flibanserin (Addyi) and muscle preservation strategies for premenopausal women with HSDD, covering pharmacology, drug interactions, lifestyle co-management, and evidence-based protocols.
A clinical breakdown of flibanserin (Addyi) patent status, regulatory exclusivity, generic approval pathway, and projected availability dates for generic versions.
Complete pharmacokinetic profile of flibanserin (Addyi) including absorption, distribution, CYP3A4 metabolism, elimination half-life, food effects, and clinical implications for HSDD treatment.
Flibanserin (Addyi) stopped working or never worked? This MD-level guide covers every evidence-based reason for plateau and non-response, with dosing strategies, drug interactions, and when to switch therapies.
Complete clinical guide to the flibanserin (Addyi) pre-surgery hold window: why a 7-day washout is required before any procedure involving anesthesia, which interactions drive the risk, and how to restart safely.
A clinical review of flibanserin (Addyi) real-world evidence from registries, post-market surveillance, and observational studies, including mechanism of action and effectiveness outside clinical trials.
An evidence-based guide to flibanserin (Addyi) discontinuation. Learn whether rebound HSDD occurs after stopping, what withdrawal symptoms are reported, and how to taper safely.
A clinician-level review of flibanserin (Addyi) and kidney safety: pharmacokinetics, renal dosing, drug interactions, and what current evidence says about renal protection versus renal risk.
Complete guide to flibanserin (Addyi) storage conditions, shelf life, stability data, and mechanism of action. with FDA and PubMed citations.
A complete guide to Aetna CVS Health coverage for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, appeal strategy, and cost-saving options for premenopausal women with HSDD.
A clinical and coverage guide to Anthem (Elevance Health) prior authorization, step therapy, formulary tier, and appeal pathways for Addyi (flibanserin) for HSDD in premenopausal women.
A clinical guide to Humana coverage of Addyi (flibanserin) for HSDD: formulary tiers, prior authorization requirements, step therapy, appeal pathways, and out-of-pocket cost options.
A detailed guide to Kaiser Permanente's coverage policy, prior-authorization requirements, formulary tier, step-therapy rules, and appeal process for Addyi (flibanserin) for HSDD.
A detailed look at Medicare Advantage coverage policies for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary status, appeal rights, and cash-pay alternatives for premenopausal women with HSDD.
A state-by-state guide to Medicaid coverage of flibanserin (Addyi) for HSDD: formulary status, prior authorization criteria, step therapy requirements, appeal rights, and cost alternatives.
Find out whether TRICARE covers Addyi (flibanserin) for HSDD, what prior-authorization criteria apply, how step therapy works, and exactly how to appeal a denial. prepared by the HealthRX.com Editorial Team.
A guide to UnitedHealthcare coverage for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary tier placement, appeals, and cost-saving strategies for HSDD treatment.
A clinician-grade guide to every major flibanserin (Addyi) drug interaction, including CYP3A4 inhibitors, alcohol, CNS depressants, hormonal contraceptives, and P-gp substrates, with FDA and PubMed citations.
Flibanserin is contraindicated in all degrees of hepatic impairment due to a 4.5-fold increase in drug exposure. Learn the pharmacokinetic data, FDA warnings, and clinical alternatives.
A clinician-grade review of flibanserin off-label uses beyond FDA-approved HSDD in premenopausal women, with trial data, evidence grading, and safety considerations for each indication.
Flibanserin (Addyi) is not approved, studied, or indicated for pediatric use. Learn why no safety data exists for children under 12 and what the FDA labeling states.
Evidence-based guide to safely discontinuing flibanserin (Addyi), including taper considerations, timeline expectations, and what to discuss with your prescriber before stopping.
Evidence-based guide to switching from flibanserin (Addyi) to bremelanotide (Vyleesi) or other HSDD treatments, including washout periods, dose adjustments, and clinical monitoring.